Midtreatment 18F-FDG PET/CT scan for early response assessment of SMILE therapy in natural killer/T-cell lymphoma: A prospective study from a single center

Journal of Nuclear Medicine

Volumn 55, Issue 6, 2014, Pages 911-916

  Khong, Pek Lan ^a   Huang, Bingsheng ^a   Lee, Elaine Yuen Phin ^a   Chan, Winnie Kit Sum ^a   Kwong, Yok Lam ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Deauville score (DS); Extranodal natural killer T cell lymphoma (ENKTL); Response assessment

Indexed keywords

ASPARAGINASE; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE; METHOTREXATE; PREDNISOLONE; ANTINEOPLASTIC AGENT;

ACCURACY; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DEAUVILLE 5 POINT SCORE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; MALE; MAXIMUM STANDARDIZED UPTAKE VALUE; MULTIPLE CYCLE TREATMENT; NK T CELL LYMPHOMA; ONCOLOGICAL PARAMETERS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; LYMPHOMA, T-CELL; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; SCINTISCANNING; TIME; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; ETOPOSIDE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IFOSFAMIDE; LYMPHOMA, T-CELL; MALE; METHOTREXATE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PREDNISOLONE; PROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903214688     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.131946     Document Type: Article

References (23)

1. Tse E, Kwong YL. How I treat NK/T-cell lymphomas. Blood. 2013;121:4997-5005.
2. Au WY, Ma SY, Chim CS, et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol. 2005;16:206-214.
3. Kako S, Izutsu K, Ota Y, et al. FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol. 2007;18:1685-1690. (Pubitemid 47506256)
4. Khong PL, Pang CBY, Liang R, Kwong YL, Au WY. Fluroine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann Hematol. 2008;87:613-621.
5. 18F-FDG PET/CT for initial staging of nasal type natural killer/T-cell lymphoma: a comparison with conventional staging methods. J Nucl Med. 2013;54:1039-1044.
6. 18F-FDG PET/CT for staging NK/T-cell lymphomas. Nucl Med Commun. 2010;31:195-200.
7. Chan WKS, Au WY, Wong CYO, et al. Metabolic activity measured by F-18 FDG PET in NK-cell lymphoma compared to aggressive B- and T-cell lymphomas. Clin Nucl Med. 2010;35:571-575.
8. 18F-FDG PET/CT in patients with extranodal NK/T-cell lymphoma. Eur J Nucl Med Mol Imaging. 2013;40:1321-1329.
9. Song MK, Chung JS, Shin HJ, et al. Clinical value of metabolic tumor volume by PET/CT in extranodal natural killer/T cell lymphoma. Leuk Res. 2013;37:58-63.
10. 18F-FDG uptake in patients with untreated extranodal natural killer/T-cell lymphomas of the head and neck. J Nucl Med. 2008;49:1783-1789.
11. 18F- fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group. Ann Oncol. 2011;22:705-711.
12. 18F-FDG PET/CT in patients with mature T-cell and natural killer cell lymphoma. J Nucl Med. 2013;54:507-515.
13. Kwong YL, Kim WS, Lim ST, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012;120:2973-2980.
14. Meignan M, Gallamini A, Meignan M, et al. Report on the first international workshop on interim-PET scan in lymphoma. Leuk Lymphoma. 2009;50:1257-1260.
15. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERSIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(suppl 1):122S-150S.
16. Chim CS, Ma SY, Au WY, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood. 2004;103:216-221.
17. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571-578. (Pubitemid 350002965)
18. Meignan M, Gallamini A, Itti E, Barrington S, Haioun C, Polliack A. Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Mention 2011 consensus. Leuk Lymphoma. 2012;53:1876-1881.
19. Biggi A, Gallamini A, Chauvie S, et al. International validation study for interim PET in ABVD-treated advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med. 2013;54:683-690.
20. 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007;48:1626-1632.
21. 18F-FDG PET in patients with diffuse large B-cell lymphomas: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med. 2009;50:527-533.
22. Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 2011;118:37-43.
23. Pregno P, Chiappella A, Bellò M, et al. The interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood. 2012;119:2066-2073.